AgomAb Therapeutics
PublicAgomAb Therapeutics is now publicly traded
The data on this page reflects AgomAb Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 9, 2026
Last Round
Series D
Oct 24, 2024
Total Funding Raised
$527M
Company Overview
AgomAb Therapeutics is a biopharmaceutical company that develops disease-modifying therapies for fibro-inflammatory diseases by targeting established pathways and utilizing organ-restricted approaches.
Sector
Biotech
Verticals
Life Sciences
AI Layer
Non-AI
Keywords
AgomAb Therapeutics Comparables
Compare AgomAb Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pliant Therapeutics | 85% | |
| Mediar Therapeutics | 83% | |
| Alentis Therapeutics | 81% |
For institutional investors. Book with your work email.
AgomAb Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Feb 9, 2026 | ||||
| Series D | Oct 24, 2024 | ||||
| Series C | Oct 11, 2023 | ||||
| Series B Extension | Jul 13, 2022 | ||||
| Series B | Mar 10, 2021 | ||||
Series A Extension | Oct 10, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AgomAb Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B |
| Asabys Partners | Series B Extension, Series D |
| Van Lanschot Kempen | IPO |
| Boehringer Ingelheim | Series B, Series A |
| Kohlberg Kravis Roberts | Series C |
| EQT Life Sciences | Series C |
| Morgan Stanley & Co., LLC | IPO |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 9, 2026
Agomab plans to present STENOVA open-label extension data for ontunisertib and host a scientific symposium focused on fibro-inflammation at UEG Week 2026.
- hiresSep 11, 2026
On Aug 10th '26, Agomab proposes appointing Marino Garcia as a non-executive member of its Board of Directors alongside Naimish Patel, M.D., subject to shareholder approval at its Sep 11th '26 Special General Meeting in Belgium.
- hiresSep 11, 2026
Agomab appoints Naimish Patel, M.D., as a non-executive member of its Board of Directors after shareholders approve the appointment in Belgium on Sep 11th '26.
For institutional investors. Book with your work email.
AgomAb Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.